endometrial cancer
Conditions
Interventions
Sponsors
International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Women aged >=18 years, with a history of sexual activity and who are not pregnant, Meeting at least one of the following high-risk factors 2-21, with clinical suspicion of endometrial cancer or endometrial atypical hyperplasia,Clinical suspicion of endometrial cancer or endometrial atypical hyperplasia; 2.Abnormal uterine bleeding (AUB); 3. Postmenopausal endometrial thickening (>4 mm) detected by imaging; 4.Postmenopausal bleeding (PMB); 5. Imaging findings suggesting intrauterine occupying lesions or uneven endometrium. 6.Obesity [body mass index (BMI) >=28 kg/m^2]; 7.Diabetes; 8.Hypertension; 9.Polycystic ovary syndrome (PCOS); 10.Ovulatory dysfunction; 11. >45 years old and nulliparous or with primary infertility; 12.Early menarche (55 years); 14.Perimenopausal transition (>40 years to menopause); 15.History of hormone replacement therapy (duration >=5 years); 16.Long-term use of tamoxifen (duration >=2 years); 17.Ovarian sex cord-stromal tumors; 18.Patients with Lynch syndrome; 19.First- to third-degree relatives with Lynch syndrome but no genetic testing performed in the individual; 20.Family history of endometrial cancer or colorectal cancer; 21.Patients suspected of endometrial cancer by a physician due to other signs, family history, genetic factors, etc.
Exclusion criteria
Exclusion criteria: 1.Women with a history of histopathologically confirmed and treated endometrial atypical hyperplasia or endometrial cancer. 2.Individuals who have previously undergone a total hysterectomy. 3.Subjects unable to cooperate with or tolerate the positioning required for the examination. 4.Patients with severe or unstable underlying medical conditions (e.g., cardiac, pulmonary, hepatic, renal, or hematologic diseases) for whom, in the investigator's assessment, the risks associated with undergoing the study-related procedures outweigh the potential benefits. 5.Subjects with anatomical abnormalities (e.g., cervical stenosis, cervical atresia, or a stenotic/obliterated cervical os) that preclude the performance of hysteroscopy. 6.Individuals who are scheduled or anticipated to undergo a hysterectomy in the near future due to other clinical indications. 7.Subjects who refuse to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| DNA methylation;Endometrial Cytology Test;Hysteroscopy;AUC; | — |
Countries
China
Contacts
Public ContactYudong Wang
International Peace Maternity and Child Health Hospital, Shanghai Jiaotong University School of Medicine
Outcome results
None listed